A preview of the emerging health care companies profiled in the current, all-profiles issue of Start-Up. This month's profile groups are "Glioblastoma Start-Ups Get Specific," "Glaucoma Start-Ups Reach Critical Mass," and "ALS on the Cusp." Plus these Start-Ups Across Health Care: EarlySense, NeoChord, and Pantec Biosolutions.

The infertility market has historically been dominated by drugs. There have been few product opportunities on the medtech side, which has consisted of commodity products like syringes, petri dishes and microscopes. But that is changing; recently several new companies have been founded with technologies to improve the success rates of in vitro fertilization. VCs have also come to realize that infertility represents a premium, self-pay market for elective procedures.

Cell Medica is pursuing what could be considered a relatively low-tech, low-risk approach to T-cell immunotherapy. The two-year-old spin-out of Imperial Innovations Group will treat immunosuppressed bone marrow donation recipients with T cells isolated from their bone marrow donors. The company's first project is in isolating cytomegalovirus-specific T cells from donors for infusion into patients who are at particular risk of CMV infection following bone marrow transplant.